Easy Bio이지바이오
353810 · KOSDAQ · ₩353810 · 이지바이오
₩5,300▲ ₩110 (2.12%)End-of-day · Oct 27, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩477B | ₩384B | ₩165B | ₩156B | ₩129B |
| Cost of sales | ₩356B | ₩286B | ₩113B | ₩107B | ₩89B |
| Gross profit | ₩121B | ₩98B | ₩52B | ₩49B | ₩41B |
| Operating income | ₩45B | ₩32B | ₩21B | ₩16B | ₩17B |
| Net income | ₩29B | ₩20B | ₩16B | ₩9.3B | ₩11B |
| Net income to shareholders | ₩28B | ₩20B | ₩16B | ₩9.1B | ₩11B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩327B | ₩360B | ₩172B | ₩158B | ₩118B |
| Current assets | ₩189B | ₩219B | ₩120B | ₩107B | ₩65B |
| Cash and equivalents | ₩60B | ₩60B | ₩29B | ₩40B | ₩21B |
| Total liabilities | ₩214B | ₩271B | ₩106B | ₩105B | ₩72B |
| Current liabilities | ₩140B | ₩128B | ₩72B | ₩85B | ₩64B |
| Borrowings | ₩152B | ₩189B | ₩51B | ₩81B | ₩50B |
| Total equity | ₩114B | ₩89B | ₩66B | ₩53B | ₩45B |
| Shareholders' equity | ₩107B | ₩84B | ₩63B | ₩50B | ₩43B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩35B | ₩26B | ₩34B | −₩8.1B | ₩14B |
| Capital spending | ₩5.9B | ₩4.2B | ₩1.9B | ₩2B | ₩1.8B |
| Free cash flow | ₩29B | ₩22B | ₩32B | −₩10B | ₩12B |
| Dividends paid | ₩6.7B | ₩3.4B | ₩2.6B | ₩2.6B | ₩2.6B |
Consolidated where available. Amounts in won.
Also known as: Easy Bio / 이지바이오 / 353810 / KRX:353810
Source: KRX statistical information